NASDAQ:OREX Orexigen Therapeutics (OREX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free OREX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.22▼$0.3250-Day Range$0.22▼$0.2252-Week Range$0.17▼$3.81Volume3.74 million shsAverage Volume1.16 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orexigen Therapeutics alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Orexigen Therapeutics Stock (NASDAQ:OREX)Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… OREX Stock News HeadlinesApril 17, 2024 | businesswire.comXeno Biosciences Announces New CEO and FinancingAugust 27, 2023 | thestreet.comOrexigen Tanks After-Hours on Obesity DataApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.August 9, 2023 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent UpdatesJuly 20, 2023 | finance.yahoo.comTriumvira Immunologics Strengthens its Leadership Team with Three Accomplished Life Sciences ExecutivesJune 20, 2023 | markets.businessinsider.comMAPLIGHT THERAPEUTICS APPOINTS KRIS HANSON AS GENERAL COUNSELMay 17, 2023 | marketwatch.com2023 "Anti-obesity Drugs Market" Key Manufacturers and Regional Outlook 2031May 16, 2023 | marketwatch.comGlobal Anti-obesity Medicine Market Size 2023-2031 Market Dynamics by Absolute Reports | with [86 Pages]April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 5, 2023 | marketwatch.comThe global Weight Loss Therapeutics market Size during the period of 2023 to 2030 is expected grow at CAGR of 11.3%March 30, 2023 | finance.yahoo.comZevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of DirectorsMarch 30, 2023 | marketwatch.comAnti-Obesity Drugs Market Factual Overview Research Report 2023-2030March 29, 2023 | marketwatch.comGlobal Anti-Obesity Drugs Market Size 2023 to 2026 Size and Share Survey ReportMarch 28, 2023 | marketwatch.comAnti Obesity Drugs Market Size and Forecast till 2028March 28, 2023 | marketwatch.comAnti-Obesity Drugs Market New Innovations and Future Expansion 2023-2031March 21, 2023 | marketwatch.comAnti-Obesity Drugs (Anti-obesity Medication) Market Share and Forecast till 2028March 13, 2023 | marketwatch.comAnti Obesity Drugs Market Continues Aggressive Growth till 2028March 8, 2023 | marketwatch.comThe Weight Loss Therapeutics Market 2023 is Expected to Udergo Significant Changes Due to New Technologies and Other Industry Related Factors 2030March 6, 2023 | marketwatch.com2023-2029 Anti-Obesity Prescription Drugs Market Size and Growth Analysis | Research Report by Absolute ReportsFebruary 23, 2023 | marketwatch.comAnti-obesity Drugs Market International Business Analysis, Development Outlook and Regional Strategies 2028December 8, 2022 | marketwatch.comWeight Loss Therapeutics Market Shows Huge Demand by Shares, Size, Future Trends and Future Scope Including Top Players by 2023-2028November 18, 2022 | marketwatch.comAnti-obesity Medicine Market 2023 | Future Growth Segments, Latest Opportunities, Industry Revenue, Size, Share and Leading Players Forecast to 2028October 13, 2022 | marketwatch.comWeight Loss Therapeutics Market Size And Opportunities for New Players, Forecast from 2022 To 2028September 6, 2022 | thestreet.comOrexigen to Post Obesity Data in Race With Vivus, ArenaSeptember 6, 2022 | marketwatch.comObesity Management Market Size 2022 : Technological Advancements in Report & Recent Innovations, Value Chain Analysis Till 2028 | 87 Report PagesAugust 22, 2022 | thestreet.comOrexigen Weight-Loss Pill Shows Surprise Heart-Safety BenefitAugust 17, 2022 | marketwatch.comAnti-obesity Drugs Market Size 2022 Share, Growth By Top Company, Business Opportunity, Region, Application, Driver, Trends and Forecasts By 2028See More Headlines Receive OREX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orexigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2017Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:OREX CUSIP68616410 CIK1382911 Webwww.orexigen.com Phone858-875-8600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael A. Narachi (Age 59)Pres, Chief Exec. Officer & Director Dr. Thomas R. Cannell D.V.M. (Age 56)Exec. VP, COO & Pres of Global Commercial Products Mr. Thomas P. Lynch (Age 51)Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. Ms. Monica Forbes (Age 42)VP & Acting CFO Mr. Stephen A. Moglia (Age 53)Chief Accounting Officer, VP and Controller Key CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors OREX Stock Analysis - Frequently Asked Questions How were Orexigen Therapeutics' earnings last quarter? Orexigen Therapeutics, Inc. (NASDAQ:OREX) released its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to analyst estimates of $24.20 million. The firm's revenue for the quarter was up 170.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.12 EPS. What other stocks do shareholders of Orexigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), ImmunoGen (IMGN), MannKind (MNKD), Novavax (NVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP) and Biogen (BIIB). This page (NASDAQ:OREX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport SocietyGreat Crypto BullWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orexigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
